Lenvatinib plus pembrolizumab (L plus P) vs sunitinib (S) in advanced renal cell carcinoma (aRCC): Patterns of progression and subsequent therapy in the CLEAR trial

被引：0
|
作者：
Grunwald, Viktor
Motzer, Robert J.
Keizman, Daniel
Bedke, Jens
Schmidinger, Manuela
Staehler, Michael D.
Matveev, Vsevolod B.
George, Saby
Hutson, Thomas E.
Vaishampayan, Ulka N.
Merchan, Jaime R.
Eto, Masatoshi
Rha, Sun Young
Waddell, Tom
Sabbatini, Roberto
Barthelemy, Philippe
Burgents, Joseph E.
Ren, Min
Brown, Ian
Choueiri, Toni K.
机构：
[1] Univ Hosp Essen, Essen, Germany
[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[3] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel
[4] Klinikum Stuttgart, Dept Urol, Stuttgart, Germany
[5] Klinikum Stuttgart, Eva Mayr Stihl Canc Ctr, Stuttgart, Germany
[6] Med Univ Vienna, Vienna, Austria
[7] Univ Hosp Munich, Munich, Germany
[8] Minist Hlth Russian Federat, State Budgetary Inst NN Blokhin Natl Med Res Ctr, Moscow, Russia
[9] Roswell Park Canc Inst, Buffalo, NY 14263 USA
[10] Texas Oncol, Dallas, TX USA
[11] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI 48109 USA
[12] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
[13] Kyushu Univ, Fukuoka, Japan
[14] Yonsei Univ Hlth Syst, Yonsei Canc Ctr, Seoul, South Korea
[15] Christie NHS Fdn Trust, Manchester, Lancs, England
[16] Univ Hosp Modena, Modena, Italy
[17] Strasbourg European Canc Inst, Strasbourg, France
[18] Merck & Co Inc, Rahway, NJ 07065 USA
[19] Eisai Inc, Nutley, NJ USA
[20] Eisai Ltd, Hatfield, Herts, England
[21] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4524
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Characteristics and management of major adverse events in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab based on results from the CLEAR trial
    Motzer, R.
    George, S.
    Merchan, J. R.
    Hutson, T. E.
    Song, X.
    Perini, R. F.
    Xie, R.
    Bapat, U.
    Puente, J.
    ONKOUROLOGIYA, 2023, 19 (02): : 29 - 40
  • [42] Integrating peripheral biomarker analyses from JAVELIN Renal 101: Avelumab plus axitinib (A plus Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).
    Choueiri, Toni K.
    Donahue, Amber C.
    Rini, Brian I.
    Powles, Thomas
    Haanen, John B. A. G.
    Larkin, James
    Mu, Xinmeng Jasmine
    Pu, Jie
    Thomaidou, Despina
    Di Pietro, Alessandra
    Robbins, Paul B.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [43] Nivolumab plus cabozantinib (N plus C) vs sunitinib for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial
    Pook, David
    Powles, Thomas
    Burotto, Mauricio
    Bourlon, Maria T.
    Hsieh, James J.
    Basso, Umberto
    Shah, Amishi Y.
    Suarez, Cristina
    Porta, Camillo
    Barrios, Carlos
    Gurney, Howard
    Kessler, Elizabeth R.
    Retz, Margitta
    George, Saby
    Escudier, Bernard
    Zhang, Joshua
    Simsek, Burcin
    Scheffold, Christian
    Motzer, Robert J.
    Choueiri, Toni K.
    Apolo, Andrea B.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 131 - 131
  • [44] Subsequent therapy following pembrolizumab plus axitinib or sunitinib treatment for advanced renal cell carcinoma (RCC) in the phase III KEYNOTE-426 study
    Gafanov, R.
    Powles, T. B.
    Bedke, J.
    Stus, V.
    Waddell, T. S.
    Nosov, D.
    Pouliot, F.
    Soulieres, D.
    Melichar, B.
    Azevedo, S.
    McDermott, R. S.
    Vynnychenko, I. O.
    Borchiellini, D.
    Markus, M.
    Bondarenko, I.
    Lin, J.
    Burgents, J.
    Molife, L. R.
    Plimack, E. R.
    Rini, B.
    ANNALS OF ONCOLOGY, 2021, 32 : S694 - S694
  • [45] Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study
    Motzer, Robert J.
    Porta, Camillo
    Eto, Masatoshi
    Powles, Thomas
    Gruenwald, Viktor
    Hutson, Thomas E.
    Alekseev, Boris
    Rha, Sun Young
    Merchan, Jaime
    Goh, Jeffrey C.
    Lalani, Aly-Khan A.
    De Giorgi, Ugo
    Melichar, Bohuslav
    Hong, Sung-Hoo
    Gurney, Howard
    Mendez-Vidal, Maria Jose
    Kopyltsov, Evgeny
    Tjulandin, Sergei
    Gordoa, Teresa Alonso
    Kozlov, Vadim
    Alyasova, Anna
    Winquist, Eric
    Maroto, Pablo
    Kim, Miso
    Peer, Avivit
    Procopio, Giuseppe
    Takagi, Toshio
    Wong, Shirley
    Bedke, Jens
    Schmidinger, Manuela
    Rodriguez-Lopez, Karla
    Burgents, Joseph
    He, Cixin
    Okpara, Chinyere E.
    Mckenzie, Jodi
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (11) : 1222 - 1228
  • [46] Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a firstline treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study).
    Motzer, Robert J.
    Porta, Camillo
    Eto, Masatoshi
    Powles, Thomas
    Grunwald, Viktor
    Hutson, Thomas E.
    Alekseev, Boris
    Rha, Sun Young
    Kopyltsov, Evgeny
    Mendez Vidal, Maria Jose
    Hong, Sung-Hoo
    Kapoor, Anil
    Gordoa, Teresa Alonso
    Goh, Jeffrey C.
    Merchan, Jaime R.
    Smith, Alan D.
    Mody, Kalgi
    Perini, Rodolfo F.
    Xing Dongyuan
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [47] Avelumab plus axitinib vs. sunitinib for advanced renal-cell carcinoma
    Zhang, Yue
    Wu, Shenhong
    TRANSLATIONAL CANCER RESEARCH, 2019, 8 : S585 - S588
  • [48] LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma
    Choueiri, Toni K.
    Powles, Thomas
    Voss, Martin H.
    Plimack, Elizabeth R.
    Gurney, Howard
    Song, Yue
    Perini, Rodolfo F.
    Rodriguez-Lopez, Karla
    Rini, Brian, I
    FUTURE ONCOLOGY, 2023, 19 (40) : 2631 - 2640
  • [49] Survival by depth of response and efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma: analysis of the phase 3 randomized CLEAR study
    Gruenwald, V.
    Powles, T.
    Kopyltsov, E.
    Kozlov, V.
    Alonso-Gordoa, T.
    Eto, M.
    Hutson, T.
    Motzer, R.
    Winquist, E.
    Maroto, P.
    Keam, B.
    Procopio, G.
    Wong, S.
    Melichar, B.
    Rolland, F.
    Oya, M.
    Rodriguez-Lopez, K.
    Saito, K.
    McKenzie, J.
    Porta, C.
    ONKOUROLOGIYA, 2023, 19 (04): : 32 - 43
  • [50] Patterns of progression in patients treated with nivolumab plus ipilimumab (NIVO plus IPI) versus sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214.
    Tannir, Nizar M.
    Motzer, Robert J.
    Albiges, Laurence
    Plimack, Elizabeth R.
    George, Saby
    Powles, Thomas
    Donskov, Frede
    Rini, Brian, I
    Grunwald, Viktor
    Hammers, Hans J.
    Choueiri, Toni K.
    Gurney, Howard
    Tykodi, Scott S.
    Porta, Camillo
    Burotto, Mauricio
    Tomita, Yoshihiko
    Lee, Chung-Wei
    Tang, Chad
    McDermott, David F.
    McKay, Rana R.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
12345